Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

Meanwhile, in a recent clinical trial, Amgen's experimental weight-loss drug fell short of expectations, causing a 12% dip in ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

Amgen Obesity Drug Cut Weight In Closely Watched Study Study ... that the company is encouraged by White House proposals that could support patients using weight-loss drugs, but cautioned that it is ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

The thyroid medication levothyroxine may be associated with bone loss, according to a study that will be presented at the ...

Amgen Inc.’s stock was down 7% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed ...

Amgen's phase 2 data disappointed, but its obesity pipeline still holds potential. See why AMGN stock is appealing even without the full upside from MariTide.

The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...

MariTide’s Phase 2 press release “underwhelms” with 20% weight loss from Cohort A and 17% weight loss from Cohort B at 52-weeks, with it being unclear if these are placebo adjusted. MariTide’s weight ...

Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...